Payment overview · 2025
General Payments
$808.91
39 reported records · 18 companies
Healthcare provider profile · identity verified
Jyoti Sharma
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · PHOENIX, AZ · NPI 1174996870
Verified facts
What the public records show
CMS Open Payments records show Jyoti Sharma received $808.91 in general payments during 2025 across 39 reported records.
Novartis Pharmaceuticals Corporation accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $221.28 | 27.4% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.34 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.77 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.78 | 7.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.95 | 6.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.56 | 6.0% | 2 | 2025 |
| ZOLL Respicardia, Inc. | Unresolved — no canonical attribution shown | $38.63 | 4.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.28 | 4.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $34.48 | 4.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $31.21 | 3.9% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $22.45 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.81 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.64 | 2.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.47 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.81 | 2.1% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.87 | 2.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $13.89 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $808.91 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $152.14 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.34 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $74.65 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $69.14 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $66.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.78 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.95 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.56 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| remede System Normalized: remede system |
Device | ZOLL Respicardia, Inc. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $36.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.62 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $31.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 302 | 113 |
| Losartan Potassium | Losartan Potassium | 220 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 76 |
| Lisinopril | Lisinopril | 196 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 67 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 167 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 158 | 43 |
| Gabapentin | Gabapentin | 151 | 64 |
| Carvedilol | Carvedilol | 143 | 61 |
| Metformin Hcl | Metformin Hcl | 142 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 44 |
| Tramadol Hcl | Tramadol Hcl | 110 | 40 |
| Meloxicam | Meloxicam | 101 | 34 |
| Farxiga | Dapagliflozin Propanediol | 89 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 31 |
| Eliquis | Apixaban | 82 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 43 |
| Alendronate Sodium | Alendronate Sodium | 77 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 31 |
| Omeprazole | Omeprazole | 72 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 29 |
| Simvastatin | Simvastatin | 61 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Furosemide | Furosemide | 51 | 25 |
| Ozempic | Semaglutide | 51 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 19 |
| Pregabalin | Pregabalin | 47 | 18 |
| Potassium Chloride | Potassium Chloride | 44 | 22 |
| Jardiance | Empagliflozin | 43 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Prednisone | Prednisone | 37 | 26 |
| Movantik | Naloxegol Oxalate | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 15 |
| Spironolactone | Spironolactone | 35 | 16 |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 33 | 11 |
| Ibuprofen | Ibuprofen | 30 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 29 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Baclofen | Baclofen | 28 | 11 |
| Celecoxib | Celecoxib | 28 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 13 |
| Famotidine | Famotidine | 27 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $808.91 · 39 records | Novartis Pharmaceuticals Corporation | AREXVY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FREESTYLE LIBRE 3, INCEPTIV, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, LEQVIO, LifeVest, NURTEC ODT, REPATHA, TRELEGY ELLIPTA, UNITHROID, Wegovy, remede System | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error